Tipifarnib
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS mutations
Phase 2Active (encouraging efficacy noted)
Key Facts
Indication
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS mutations
Phase
Phase 2
Status
Active (encouraging efficacy noted)
Company
About Kura Oncology
Kura Oncology's mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives. Founded in 2014, the company leverages deep scientific understanding of cancer biology to develop targeted therapies for areas of high unmet need, including head and neck cancer, lung cancer, and acute leukemias. Kura's strategy involves investigating its therapies in combination with standards of care to forge new paths for durable remissions. The company is led by an experienced team and is publicly traded on NASDAQ under the ticker KURA.
View full company profile